Entrada Q2 Loss Shrinks; Data From Phase 1/2 Trials In DMD And DM1 Expected In '27

(RTTNews) - Entrada Therapeutics, Inc. (TRDA) recorded a narrower loss for the second quarter ended June 30, 2026, and highlighted various clinical updates.

Company Profile

Entrada is a clinical-stage biopharmaceutical company focused on developing intracellular therapeutics for genetic diseases using its proprietary Endosomal Escape Vehicle (EEV) platform. The company's pipeline includes programs for Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and inherited retinal diseases. The company is advancing multiple clinical-stage candidates and has entered a research collaboration with Vertex Pharmaceuticals.

Q2 FY26 Highlights

Net loss for the second quarter narrowed to $42.76 million, or $1.01 per share, compared to $43.10 million or $1.04 per share in the previous year. The marginal decrease in loss was attributable to lower operating expenses.

Collaboration revenue was $0.89 million for the second quarter, while collaboration revenue in the second quarter of 2025 was $1.95 million.

Cash, cash equivalents and marketable securities amounted to $223 million as of June 30, 2026. The company expects the current cash runway to fund operations through the third quarter of 2027.

Clinical Updates & Upcoming Milestones

ENTR-601-44 (DMD Exon 44):

Entrada completed enrollment of Cohort 2 in the Phase 1/2 ELEVATE-44-201 trial evaluating ENTR-601-44 in patients with Duchenne muscular dystrophy amenable to exon 44 skipping. Earlier data from Cohort 1 demonstrated favorable safety and tolerability for the drug, along with early improvements in functional measures versus placebo. The company expects to report data from the Cohort 1 open-label period by year-end 2026, followed by Cohort 2 data in the first quarter of 2027.

ENTR-601-45 (DMD Exon 45):

Entrada completed enrollment and dosing of Cohort 1 in the Phase 1/2 ELEVATE-45-201 trial of ENTR-601-45, and has initiated Cohort 2 after an independent committee recommended dose escalation based on favorable safety data. The company expects to report Cohort 1 data in October 2026 and Cohort 2 data in the first half of 2027.

ENTR-601-50 (DMD Exon 50):

Entrada received U.K. regulatory authorization to initiate the Phase 1/2 ELEVATE-50-201 trial of ENTR-601-50 in patients with DMD amenable to exon 50 skipping. The company plans to submit additional global regulatory applications after reviewing data from its ongoing lead programs.

ENTR-601-51 (DMD Exon 51):

Entrada completed studies to enable a clinical trial application (CTA) for ENTR-601-51, its candidate for patients with DMD amenable to exon 51 skipping, and plans to submit global regulatory applications following a review of data from its lead clinical programs.

VX-670 (Myotonic Dystrophy Type 1):

The company's partner Vertex Pharmaceuticals completed enrollment in the Phase 1/2 GALILEO trial of VX-670 for myotonic dystrophy type 1 (DM1) and is currently dosing patients. Vertex expects to report trial results in the second half of 2026.

ENTR-801 (Usher Syndrome Type 2A):

Entrada is advancing ENTR-801, its lead ocular candidate for Usher syndrome type 2A, in preclinical development and plans to announce a second ocular clinical candidate and provide an update on its clinical development strategy in the second half of 2026.

TRDA closed Thursday at $6.87, down 2.69%.